Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 7/20 | 0.57 |
| ▸ | RARB | P10826 | 6/20 | 0.57 |
| ▸ | RARG | P13631 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.57 |
| ▸ | GOT1 | P17174 | 1/20 | 0.57 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9126386 | 0.93 | RARA (0.58) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL5081692 | 0.91 | RARA (0.56) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL6571365 | 0.90 | RARA (0.55) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL5078191 | 0.89 | RARA (0.67) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL9123398 | 0.88 | RARA (0.53) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL9127710 | 0.87 | KMT2A (0.57) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL8461975 | 0.86 | RARA (0.61) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL9131336 | 0.85 | RARA (0.62) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL9124887 | 0.85 | RARA (0.46) | RARARARBRARGKMT2AMEN1 | |
| SCHEMBL8459188 | 0.85 | KMT2A (0.57) | RARARARBRARGKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0409728-B1 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CIRD GALDERMA (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5468897-A | Bi-aromatic esters, a process for their preparation and their use in human or veterinary medicine and in cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-11-21 | — | — | US | disclosed |
| EP-0409728-B1 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CIRD GALDERMA (FR) | 1995-03-01 | — | — | EP | disclosed |
| US-5332856-A | Treatment of a dermatologic, rheumatismal, respiratory or ophthalmologic ailment | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5200550-A | Administering for dermatologic, rheumatismal, respiratory or ophthalomologic disorders | CENTRE INTERNATIONAL DE RECHERCES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1993-04-06 | — | — | US | disclosed |
| EP-0409728-A2 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARA 1211/4885RARB 987/4885RARG 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.